Neuren Pharmaceuticals advances NNZ-2591 for Phelan-McDermid syndrome to Phase 3 clinical trial
Neuren Pharmaceuticals has secured approval from the United States Food and Drug Administration (FDA) to progress into the first-ever pivotal Phase 3 clinical trial of NNZ-2591, a potential treatment for Phelan-McDermid syndrome (PMS). This landmark development is the outcome of a constructive End of Phase 2 meeting with the FDA, during which critical design aspects […]
